STAT+: ‘A tug of war’: Europe braces for new legislation with far-reaching impacts on pharma and patients
After more than two years of planning, the European Commission on Wednesday will release long-awaited…
Category: Pharma
STAT+: Pharmalittle: Lilly expects Medicare to back down on Alzheimer’s drug coverage; key senators change insulin cap proposal
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: White House to tap cancer center chief to lead NIH; generic abortion pill maker sues FDA
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
.jpg)
STAT+: Senate still hasn’t made hard decisions on lowering insulin costs
WASHINGTON — Senate Democrats are trying to cap insulin costs for every American, but they…
STAT+: PhRMA execs paint grim picture of industry under Medicare drug price negotiation
WASHINGTON — Executives for the brand drug industry’s biggest lobbying group painted a grim picture…
STAT+: STAT-Harris Poll: Most Americans are worried about RSV
A majority of Americans are concerned about the health threat posed by the respiratory syncytial…
STAT+: Pharmalittle: GSK manufacturing workers in the U.K. to strike in May; weight-loss drugs prompt strange dreams
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Leaked study results show a CAR-T from J&J providing big benefit for patients with multiple myeloma
The CAR-T cancer therapy called Carvykti, made by Johnson & Johnson and Legend Biotech, reduced…
STAT+: Mark Cuban’s drug company creates a pharmacy network to challenge PBMs
In its latest bid to upend the pharmaceutical supply chain, the Mark Cuban Cost Plus…
STAT+: Pharmalittle: GSK will buy Bellus Health for $2 billion; FDA inspectors are leaving faster than they can be replaced
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Most large U.S. funders of clinical research have poor transparency policies, analysis finds
Amid ongoing concern over clinical trial transparency, a new analysis finds that only 37% of…
STAT+: Pharmalittle: Merck to acquire Prometheus Biosciences for $10.8 billion; mRNA cancer vaccine reduces melanoma relapse
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Q&A: What does it mean when a clinical trial is delayed? More than you think
Frank David was just starting an independent research program on cell signaling in cancer and…
STAT+: Moderna’s mRNA cancer vaccine shows promise in combination with melanoma drug
ORLANDO, Fla. — For years, early experimental results offered hope that scientists might be able…
Merck to acquire Prometheus Biosciences, maker of autoimmune drugs, for $10.8 billion
Merck said Sunday that it will acquire Prometheus Biosciences for $10.8 billion, adding a pipeline…
STAT+: Pharmalittle: Telehealth abortion providers are scrambling; Express Scripts launches new pricing plan amid PBM scrutiny
And so, another working week will soon draw to a close. Not a moment too…
STAT+: ‘Style over substance?’ Express Scripts launches new pricing plan amid rising scrutiny of PBMs
Amid increasing scrutiny of pharmacy benefit managers, Express Scripts is launching a new pricing plan…
STAT+: Medicare advisers endorse reforms to lower drug spending
In the latest move to address prescription drug pricing, the Medicare Payment Advisory Commission unanimously…
STAT+: Pharmalittle: Appeals court allows access to abortion pill, but with restrictions; FDA official intervened on behalf of Sarepta gene therapy
Top of the morning to you. And a steamy one, it is. In fact, there…
STAT+: Sickle cell gene therapies could be cost-effective even if priced as high as $1.9 million
As the U.S. health care system prepares for expensive gene therapies, a preliminary analysis suggests…
STAT+: Senate hashing out policy details on generics, PBMs, insulin
WASHINGTON — Senators are slightly delaying their latest legislative push on health care, but as they…
STAT+: Pharmalittle: Where is PhRMA in the abortion pill debate? Most late-stage MS drug trials were never published
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: How many? One-third of late-stage trials testing multiple sclerosis drugs were never published
The results from more than one-third of late-stage clinical trials that tested multiple sclerosis drugs…
STAT+: Pharmalittle: Pharma execs call for reversal of abortion pill ruling; U.S. to spend $5 billion to speed Covid-19 treatments
Top of the morning to you, and a fine one it is. Clear blue skies…
STAT+: Pharmalittle: Abortion pill ruling could threaten FDA approval authority; Lilly CEO warns EU pharma legislation will hurt innovation
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Genentech finds no evidence of fraud in paper by former top exec; FDA withdraws approval for premature-birth drug
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Brazilian committee says a Vertex cystic fibrosis is not cost-effective and should not be reimbursed
A Brazilian government advisory committee recommended that the health ministry not pay for a cystic…
STAT+: FDA withdraws approval of controversial drug to prevent preterm births
After a years-long controversy, the U.S. Food and Drug Administration ordered the immediate withdrawal of a…
STAT+: Pharmalittle: Weight-loss drug ads pose new oversight challenge; will the new Bayer CEO split the company?
Rise and shine, another busy day is on the way. We can tell because the…
STAT+: Cancer drug shortages have plagued the U.S. for years. Can they be fixed?
Roughly two million Americans are expected to receive a cancer diagnosis this year. Some members…
STAT+: Pharmalittle: J&J agrees to settle talcum powder claims for $8.9 billion; FDA authorizes new severe-Covid therapy
Good morning! Jason Mast here, filling in for Ed on this fine Passover eve. Every…
STAT+: ‘True disruption’: Mark Cuban’s company will sell brand-name diabetes medicines from Janssen
For the first time, Mark Cuban’s Cost Plus Drug Company is selling medicines made by…
STAT+: Pharmalittle: A ‘King Kong’ of weight-loss drugs is looming; FTC orders Illumina to divest Grail
Hello, everyone, and how are you today? We are doing just fine, thank you, since…
STAT+: Pharmalittle: FDA slams company recalling eye drops over manufacturing issues; U.S. funds massive Alzheimer’s research database
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: The biotech scorecard for the second quarter: 24 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the second…
STAT+: European Union drug pricing proposal for the pandemic treaty generates pushback
Amid treaty talks to create equitable access to medical products during pandemics, the European Union…
STAT+: Inflation caused a sizable drop in net drug prices in late 2022, analysis finds
Amid ongoing debate over the cost of prescription medicines, a new analysis finds that brand-name…
STAT+: FDA report details problems at Global Pharma plant involved in eye drop recall
Global Pharma Healthcare, whose eye drops have been linked to dozens of serious reactions, failed…
STAT+: Pharmalittle: Judge blocks required ACA coverage for preventive care; Supreme Court urged to review skinny label case
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Solicitor General urges Supreme Court to review ‘skinny labeling’ and generic drug access
The U.S. solicitor general urged the U.S. Supreme Court to review a controversy over so-called…
STAT+: Drug middlemen switch tactics, but the outcome is the same: high prices
WASHINGTON — Prescription drug middlemen are shifting away from rebates that have been blamed in…
STAT+: Pharmalittle: FDA approves over-the-counter Narcan; J&J exits the race for the first RSV vaccine
Rise and shine, another busy day is on the way. We can tell because the…
.jpg)
STAT+: Dutch health minister won’t cover a Gilead cancer drug due to the cost
In a rare move, the Dutch health ministry refused to provide coverage for a Gilead…
STAT+: NIH releases data showing more clinical trial sponsors are reporting results, but most miss deadlines
In response to mounting criticism, the National Institutes of Health published data that shows an…
STAT+: Pharmalittle: WHO may add obesity drugs to essential medicines list; monkey shortage may delay drug development
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Shortage of monkeys for early-stage research jeopardizes timelines for developing some drugs
A growing shortage of monkeys used for early-stage pharmaceutical research is causing concern that many…
Pressure is building on pharma and biotech companies to take climate action
As the health impacts of climate change become harder to ignore, biotechnology and pharmaceutical companies…
STAT+: Pharmalittle: Ohio attorney general accuses PBMs of price fixing; how cost-effectiveness fight could hobble drug price negotiations
Top of the morning to you. Steely gray skies are hovering over the Pharmalot campus…
STAT+: Could a fight over cost-effectiveness upend Medicare drug price negotiation before it’s begun?
WASHINGTON — As Medicare drug price negotiation looms, congressional Republicans are scrambling to push through…
A half century after Prozac, a new generation of depression drugs is bringing hope to a long-stagnant field
This article is excerpted from the latest STAT Report: Treating Depression: a new era of…